Today: 29 April 2026
Browse Category

NASDAQ:KYMR 8 December 2025 - 4 January 2026

Kymera Therapeutics stock extends slide as KYMR closes down 6.5% — what investors watch next

Kymera Therapeutics stock extends slide as KYMR closes down 6.5% — what investors watch next

Kymera Therapeutics shares fell 6.5% to $72.76 on Friday, marking a seventh straight daily loss and leaving the stock down 29% from its early December peak. About 854,000 shares traded as investors shifted focus to 2026 trial milestones and funding. CEO Nello Mainolfi sold 30,000 shares in a pre-arranged plan on Dec. 31. The company raised $602 million in a December stock offering at $86 per share.
4 January 2026
·
Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching

Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching

Kymera Therapeutics shares fell 3% to $77.94 Tuesday afternoon, underperforming a 1.4% drop in the SPDR S&P Biotech ETF. The decline follows December’s $692 million equity raise and positive Phase 1b data for its STAT6 degrader KT-621. The stock traded about 9% below its recent $86 offering price. Investors are watching for updates on trial progress and cash burn ahead of 2026 milestones.
30 December 2025
··
Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update

Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update

Kymera Therapeutics shares jumped 41.6% to close at $94.30 on December 8 after its oral STAT6 degrader KT-621 showed dupilumab-like efficacy and clean safety in a small Phase 1b eczema trial. The company announced a $500 million stock offering the same day, sending shares lower in after-hours trading. Analyst price targets rose, some reaching $138.
9 December 2025
····
Kymera Therapeutics (KYMR) Stock Soars on KT‑621 Eczema Data: What December 8, 2025 Means for Investors

Kymera Therapeutics (KYMR) Stock Soars on KT‑621 Eczema Data: What December 8, 2025 Means for Investors

Kymera Therapeutics shares jumped nearly 50% Monday, closing near $96 after hitting an intraday high above $100, following strong Phase 1b results for its oral STAT6 degrader KT‑621 in atopic dermatitis. The trial showed about 98% median STAT6 degradation in blood and 94% in skin lesions. Trading volume was far above normal. Stifel raised its price target as the stock marked a new 52-week high.
8 December 2025
··

Stock Market Today

  • S&P/TSX Composite Drops 200+ Points Amid Oil Surge Past $100
    April 29, 2026, 11:59 AM EDT. Canada's S&P/TSX composite index fell over 200 points to 33,355.35, despite an energy sector boost as crude oil prices surged past US$100 a barrel, reaching US$105.31. The June crude oil contract rose by US$5.38 amid stalled Middle East peace talks. U.S. markets declined, with Dow down 273.72 points and S&P 500 slipping 8.74 points. The Canadian dollar edged slightly lower against the US dollar at 73.10 cents. June gold contracts also dropped, down US$51.10 to US$4,557.30 an ounce. The market activity reflects cautious investor sentiment despite elevated energy prices.

Latest article

Applied Materials (AMAT) Faces Fresh China Shock After U.S. Targets Hua Hong Shipments

Applied Materials (AMAT) Faces Fresh China Shock After U.S. Targets Hua Hong Shipments

29 April 2026
The U.S. Commerce Department ordered Applied Materials, Lam Research, and KLA to halt some chip-tool shipments to China’s Hua Hong, Reuters reported. The move targets shipments linked to facilities believed capable of advanced chip production. Applied reported $2.10 billion in China revenue last quarter, or 30% of its total. Shares in Applied, Lam, and KLA traded lower after the news.
Cognizant Stock Drops As Weak Revenue Outlook Overshadows $600 Million AI Deal

Cognizant Stock Drops As Weak Revenue Outlook Overshadows $600 Million AI Deal

29 April 2026
Cognizant forecast second-quarter revenue below analyst estimates and announced Project Leap, a cost-cutting program focused on workforce reductions. Shares fell $1.67 to $53.45. The company reported first-quarter revenue of $5.41 billion, up 5.8%, and agreed to acquire AI infrastructure firm Astreya for about $600 million.
ON Semiconductor Stock Jumps as Geely and NIO Deals Put 900V EV Chips in Focus

ON Semiconductor Stock Jumps as Geely and NIO Deals Put 900V EV Chips in Focus

29 April 2026
ON Semiconductor shares jumped 8% Wednesday after announcing expanded silicon carbide chip deals with Geely Auto Group and NIO Inc., both focused on 900-volt electric vehicle platforms. The company’s market value reached about $41.2 billion ahead of first-quarter results due May 4. Investors are watching whether new auto-chip wins can offset uneven demand.
Go toTop